Previous 10 | Next 10 |
-- Complete data from PROTECT trial shows 89% of patients achieved the primary endpoint -- -- Additional presentations call attention to the high prevalence of gout and its associated comorbidities among individuals undergoing dialysis -- Horizon Therapeutics plc (Na...
Image source: The Motley Fool. Horizon Pharma plc (NASDAQ: HZNP) Q3 2021 Earnings Call Nov 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Horizon Pharma plc (HZNP) Q3 2021 Earnings Call Transcript
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2021 Q3 earnings call. For further details see: Horizon Therapeutics Public Limited Company 2021 Q3 - Results - Earnings Call Presentation
Horizon Therapeutics Public Limited Company (HZNP) Q3 2021 Earnings Conference Call Nov 03, 2021 08:00 AM ET Company Participants Tina Ventura - Senior Vice President, Investor Relations Tim Walbert - Chairman, President & Chief Executive Officer Liz Thompson - Executive Vice President, R...
Horizon Therapeutics (NASDAQ:HZNP) has lost ~3.8% in the pre-market despite better than expected financials posted by the company for Q3 2021. Net sales for the quarter jumped ~63% YoY to $1.0B as sales from thyroid eye disease (TED) therapy TEPEZZA more than doubled with a ~11...
-- Record Third-Quarter 2021 Net Sales of $1.037 Billion Increased 63 Percent; Third-Quarter 2021 GAAP Net Income of $326.5 Million; Record Adjusted EBITDA of $509.0 Million -- -- Record TEPEZZA ® (teprotumumab-trbw) Third-Quarter 2021 Net Sales of $616.4 Million; Inc...
Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is $1.54 (-11.5% Y/Y) and the consensus Revenue Estimate is $979.49M (+53.9% Y/Y). New long-term data on Horizon Therapeutics' Tepezza (te...
My portfolio, built specifically for my retirement ~20+ years from now, rides the September downturn in the market back under $400k. Some massive risk-on portfolio restructuring including more Bitcoin as I prepare for the seasonal Santa Claus and Bitcoin run. Making monthly contri...
Shares of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) traded at a new 52-week high today of $120.31. So far today approximately 128,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares. Horizon Therapeutics PLC is a specialty and gen...
-- Survey results of practicing rheumatologists suggest presence of negative gout stigma in causality and management of gout -- -- New analyses of real-world experience of KRYSTEXXA ® (pegloticase injection) adds to the body of data supporting the use of concomitant i...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...